Tunitas Raises $10 Million from Two China Investors

Tunitas Therapeutics, a San Francisco based biopharmaceutical company, raised $10 million in a Series A venture financing co-led by two China investors, Ally Bridge Group and WuXi Ventures. As part of the transaction, David Nikodem of Ally Bridge Group, and Sophie Qiao of WuXi Ventures have joined the Tunitas board of directors. Tunitas will use the funds to advance its lead fusion protein candidate, epsi-gam, through its initial Phase I clinical trials and the initiation of Phase IIa studies. The funding will also be used to continue the development of Tunitas' pipeline of novel targeted vaccines for the treatment of specific allergies. More details.... Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.